---
title: "Alnylam Pharmaceuticals, Inc. (ALNY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALNY.US.md"
symbol: "ALNY.US"
name: "Alnylam Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T07:12:38.032Z"
locales:
  - [en](https://longbridge.com/en/quote/ALNY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALNY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALNY.US.md)
---

# Alnylam Pharmaceuticals, Inc. (ALNY.US)

## Company Overview

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.alnylam.com](https://www.alnylam.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: B (0.28)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 10 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 82.57% |  |
| Net Profit YoY | 333.43% |  |
| P/B Ratio | 36.52 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 39267833913.00 |  |
| Revenue | 4286923000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 90.36% | A |
| Profit Margin | 12.55% | B |
| Gross Margin | 81.91% | A |
| Revenue YoY | 82.57% | A |
| Net Profit YoY | 333.43% | A |
| Total Assets YoY | 21.73% | A |
| Net Assets YoY | 831.59% | A |
| Cash Flow Margin | 132.88% | B |
| OCF YoY | 82.57% | A |
| Turnover | 0.92 | A |
| Gearing Ratio | 79.04% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Alnylam Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "82.57%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "333.43%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "36.52",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "39267833913.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4286923000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "90.36%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "12.55%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "81.91%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "82.57%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "333.43%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.73%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "831.59%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "132.88%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "82.57%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.92",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "79.04%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 72.99 | 56/386 | 1259.15 | 995.17 | 132.90 |
| PB | 36.52 | 429/386 | 267.34 | 234.04 | 55.01 |
| PS (TTM) | 9.16 | 159/386 | 23.77 | 17.00 | 11.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **29**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 15 | 52% |
| Overweight | 6 | 21% |
| Hold | 8 | 28% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 294.30 |
| Highest Target | 566.00 |
| Lowest Target | 310.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALNY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALNY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ALNY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALNY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**